These findings suggest that while COX-2 inhibitors do not impact CSC viability directly, they do influence the formation and maintenance of cancer cells, indicating a potential therapeutic role for COX-2 inhibitors in osteosarcoma treatment. This evidence concerns the gene PTGS2 and osteosarcoma.